Model-Informed Optimization of a Pediatric Clinical Pharmacokinetic Trial of a New Spironolactone Liquid Formulation

por Tatipalli, Manasa, Siripuram, Vijay Kumar, Long, Tao, Shuster, Diana, Bernstein, Galina, Martineau, Pierre, Cook, Kim A., Cristofoletti, Rodrigo, Schmidt, Stephan, Vozmediano, Valvanera
Publicado 2021

Drug–Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers...

por Polepally, Akshanth R., King, Jennifer R., Ding, Bifeng, Shuster, Diana L., Dumas, Emily O., Khatri, Amit, Chiu, Yi-Lin, Podsadecki, Thomas J., Menon, Rajeev M.
Publicado 2016

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease

por Bernstein, David E., Tran, Albert, Martin, Paul, Kowdley, Kris V., Bourliere, Marc, Sulkowski, Mark S., Pockros, Paul J., Renjifo, Boris, Wang, Deli, Shuster, Diana L., Cohen, Daniel E., Jacobson, Ira M.
Publicado 2018

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4

por Leung, Daniel H., Wirth, Stefan, Yao, Betty B., Viani, Rolando M., Gonzalez‐Peralta, Regino P., Jonas, Maureen M., Lobritto, Steven J., Narkewicz, Michael R., Sokal, Etienne, Fortuny, Clàudia, Hsu, Evelyn K., Del Valle‐Segarra, Antonio, Zha, Jiuhong, Larsen, Lois, Liu, Li, Shuster, Diana L., Cohen, Daniel E., Rosenthal, Philip
Publicado 2018